Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
Holding ABSI?
Track your performance easily
ABSI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.45 - $6.72
Previous Close$2.99
Volume2.50M
Average Volume (3M)1.49M
Market Cap
$343.42M
Enterprise Value$317.21M
Total Cash (Recent Filing)$38.20M
Total Debt (Recent Filing)$11.99M
Price to Earnings (P/E)―
Beta2.92
Next Earnings
Mar 19, 2025EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding114,855,759
10 Day Avg. Volume3,444,807
30 Day Avg. Volume1,488,646
Standard Deviation0.35
R-Squared0.08
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.71
Price to Sales (P/S)81.63
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue75.40
Enterprise Value/Gross Profit55.48
Enterprise Value/Ebitda-3.80
Forecast
1Y Price Target
$8.67Price Target Upside189.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
AbSci News
PremiumCompany Announcements
Absci Corporation Advances AI-Driven Drug Development
Bulls Say, Bears Say
Bulls Say
Market PotentialABS-101 could generate over $4 billion in peak sales despite the fierce competition in IBD.
Product DevelopmentABS-201 represents a significant opportunity due to high patient demand in androgenetic alopecia.
Technological AdvantageAbsci's AI-driven platform can design antibodies to precisely target an epitope with optimized interface contacts to ensure high potency and affinity.
Bears Say
Financial PerformanceFor 3Q24, the company reported revenues of $1.7M, compared to the consensus estimate of $1.8M, and a net loss of $0.24 per share, compared to the consensus estimated net loss of $0.19 per share.
Market CompetitionThe intensifying battle in TL1A space left some investors nervous regarding ABS-101 prospects, pressuring the stock.
Operational ExpensesQ3 OpEx of $31M was above expectations driven by higher R&D due to a jump in lab operations as the preclinical pipeline advances toward Ph1.
---
Ownership Overview
27.72% Insiders
20.57% Mutual Funds
28.09% Other Institutional Investors
8.41% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.45 and its highest was $6.72 in the past 12 months.
What is AbSci’s market cap?
Currently, no data Available
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is Mar 19, 2025 which is in 87 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Nov 12, 2024. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.194 by -$0.046.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -$0.22.
How many shares outstanding does AbSci have?
AbSci has 114,855,760 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.194. Following the earnings report the stock price went down -14.953%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
---
AbSci Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (189.97% Upside)
$8.67 (189.97% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.28%
12-Months-Change
Fundamentals
Return on Equity
-49.11%
Trailing 12-Months
Asset Growth
-0.47%
Trailing 12-Months
Company Description
AbSci
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
---
ABSI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, such as collaborations with AstraZeneca and Twist Bioscience, financial stability, and upcoming strategic events. However, it also noted increased R&D expenses, a delay in the ABS-301 program, and modest revenue figures. The positive elements slightly outweigh the negative aspects.Read More>---
ABSI Stock 12 Month Forecast
Average Price Target
$8.67
▲(189.97% Upside)
Technical Analysis
Best Analysts Covering ABSI
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
+55.83%
reiterated a buy rating 9 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +55.83% per trade.
---